Multiple Endocrine Neoplasia Type 1 (MEN1) Mutation Analysis
Multiple endocrine neoplasia type 1 (MEN-1 syndrome or Wermer's syndrome) is a rare inherited disorder presented mostly by tumors affecting the endocrine system. The disease is inherited with an autosomal dominant pattern and defined by the presence of at least two tumors from the three main endocrine sites. Patients have a decreased life expectancy (about 50% mortality by age 50).
Although many different types of hormone-producing tumors are associated with multiple endocrine neoplasia, tumors of the parathyroid gland (90-95%), pituitary gland (15-85%), and endocrine pancreas (35-80) are most frequent in MEN1. The most common manifestation of MEN 1 is hyperparathyroidism (about 90%) due to parathyroid hyperplasia (non-neoplastic overactive parathyroid gland). The second most common manifestation is islet cell tumors of the pancreas (variable, up to 80% of cases), and most of these are non-functioning. Functioning islet cell tumors include insulinoma, gastrinoma, glucagonoma, VIPoma and pancreatic polypeptidoma, of which gastrinoma is the most common. Islet cell tumors are often multicentric and may develop malignancy.
In the pituitary gland, prolactinomas are the most common (60%), followed by growth hormone-secreting tumors (25%). MEN 1-associated pituitary tumors tend to be larger and more aggressive than non-MEN1 tumors. MEN1 syndrome is caused by inactivating mutations of the MEN1 tumor suppressor gene located on chromosome 11q13 and consisting of 10 exons. The MEN1 gene is a tumor suppressor gene that codes for the 610 amino acid menin protein located within the nucleus which helps regulate several cell functions including DNA replication, repair and transcription.
More than 450 mutations have been identified in that region, which are mostly germline mutations. Genetic testing allows the early identification of germline mutations in asymptomatic carriers with the family history. The genetic testing is also used for diagnostic purposes for individuals with clinical and/or biochemical evidence of MEN1.
- Carrier screening for MEN1
- To confirm the clinical diagnosis of MEN1
Identification of a known pathogenic MEN1 mutation predicts the presence of MEN1 syndrome. Genetic analysis is also indicated for first-degree relatives of patients with MEN1 mutations, with atypical MEN1 phenotype (e.g. somatotropinoma).
The occurrence of one typical MEN1-associated neoplasm in a patient with a first-degree relative with more than one MEN1-associated tumor is sufficient for the diagnosis.
Absence of a pathogenic mutation reduces but does not exclude the possibility that the individual is affected with MEN1. Medical management should rely on clinical findings and family history. In addition to a known mutation, other MEN1 mutations of unknown clinical significance may be detected by genetic testing
Negative for mutations analyzed (Mutation not detected)
Whole blood collected with anticoagulants (Lavender EDTA tubes).
Stability
- Ambient: 5 days
- Refrigerated: 7-14 days
- Adv Exp Med Biol. 2009;668:1-15. [PMID: 20175448]
- Asia Pac J Clin Oncol. 2012 Dec 26. [PMID: 23279763]
- J Clin Endocrinol Metab. 2012 Sep;97(9):2990-3011. [PMID: 22723327]
- Nat Clin Pract Endocrinol Metab. 2008 Jan;4(1):53-8. [PMID: 18084346]
- Orphanet J Rare Dis. 2006 Oct 2;1:38. [PMID: 17014705]